UNSPSC 51171527: Betaine

This classification denotes a nutritional supplement with the molecular formula C5H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SCV180C9W, chemically known as 2-(trimethylammonio)ethanoic acid, hydroxide, inner salt but generally known as betaine, which bears US NIH Compound Identifier 247.

Betaine comes in many forms, including base, aldehyde, aldehyde chloride, aldehyde hydrate, alpha-d-glucofuranuronate, amide, aspartate, cephaloridine, chloride, choline citrate, citrate, d-galacturonate, d-gluconate, hydrate, hydrazide hydrochloride, hydrochloride, l-ascorbate, lauryldimethylaminoacetate, methyl ester, monohydrate, nicotinate, solution, and tartrate. European Medicines Agency schedules Betaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13055MIG.

UNSPSC 51171527 Betaine, a Commodity code, encompasses chemical and pharmaceutical ingredient sourcing for state and local health, corrections, and public health programs. Recent solicitations show the code capturing laboratory reagents and testing supplies for drug screening operations, pharmaceutical manufacturing inputs for state health benefit programs, and OTC product distribution through multistate cooperative purchasing vehicles. State and local buyers under this code include county corrections departments, state health and human services commissions, and multistate cooperative alliances serving multiple jurisdictions and public entities. The work ranges from specimen collection and drug-testing reagent provision (immunoassay screening supplies, confirmation reagents for LC/MS/MS or GC/MS analysis) to generic pharmaceutical sourcing and OTC product distribution under statewide or regional cooperative contracts.

Collin County in Texas and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent recent activity. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals; the scope includes lab-certified screening and confirmation testing across two collection sites with approximately 25,031 annual tests. MMCAP, administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026, with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities in Minnesota and Oregon, requiring vendors to meet cGMP and Drug Supply Chain Security Act compliance and maintain relationships with specific wholesale partners. The Texas Health and Human Services Commission also posted an RFI on April 3, 2026, regarding direct-to-manufacturer prescription programs, signaling exploratory procurement activity at the state level.